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Approximately 1.5 million neonates undergo anesthesia for surgical procedures in the
United States every year1. Notably, Midazolam, a commonly used anesthetic agent is
used in the Neonatal Intensive Care Unit (NICU) to sedate neonates and facilitate complex
procedures such as mechanical ventilation.2 One knowledge gap pertaining the use of
midazolam is its ability to affect cognitive development of infants. In 2014, the International
Anesthesia Research Society released a statement saying, “Surgeries and procedures
requiring anesthetic and sedative drugs that could reasonably be delayed should possibly
be postponed because of the potential risk to the developing brain of infants, toddlers, and
preschool children”. 3 Although some evidence has shown midazolam exposure could
harm an infant’s cognitive development, little is known about the molecular and behavioral
underpinnings and if these changes persist into adulthood. In our current study employing
a preclinical animal model system, we for the first time present a comprehensive
characterization on how early life exposure to midazolam impacts neurodevelopment
outcomes at different tiers ─ phenotypic, molecular and behavioral levels and if these
changes persist during early adulthood.
Results
Long term exposure to midazolam at early stages of life 
can potentially perturb neurodevelopmental outcomes 
that could further persist into adulthood. 
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Figure 1. Phenotypic measurements at various time points: At P7 (7 days after birth), there was a significant difference in the body weight, head size circumference, and body length 
between the saline and midazolam groups. At P14 and P21, there was only a significant difference in body weight between the saline and midazolam groups. These results suggest that 
physical growth is stunted at childhood but not adulthood. *p <0.05, ** p< 0.01; ****p< 0.0001 as determined by Two-Way ANOVA followed by a post-hoc Sidak’s test. Each bar represents the 
mean + SEM. 
Figure 2. Expression of Blood brain barrier proteins: At P21, the level of albumin, and connexin is slightly downregulated in midazolam-exposed brains, while JAM-1, Occludin, and ZO-1 levels are 
slightly upregulated. At P60, there is no difference in level of expression of albumin and JAM-1 between saline and midazolam group; however, the level of Connexin, Occludin, and ZO-1 are slightly 
decreased in midazolam-exposed brains. This suggests that Midazolam potentially alternate the regulation in key blood brain barrier proteins. Two-Way ANOVA followed by a post-hoc Sidak’s test 
revealed no significant differences (n=12/group). Each bar represents the mean + SEM.
Figure 3. Expression of synaptic proteins : Purified synaptosomes were isolated from P21 and P60 saline and midazolam animals. At P21, the level of Drebrin, EAAT2, PSD95 and 
Synaptophysin were downregulated in the midazolam exposed brains, while SNAP 25 levels are slightly upregulated.  At P60, Drebrin, EAAT2, SNAP 25, and Synaptophysin were 
downregulated in the midazolam exposed brains; however, there was no difference in the level of expression of PSD95 between the saline and midazolam groups. This suggests that midazolam 
can potentially alternate the regulation in key synaptic proteins. Two-Way ANOVA followed by a post-hoc Sidak’s test revealed no significant differences (n=12/group). Each bar represents the 
mean + SEM.
Figure 4. Behavioral tests 
(Social novelty): Throughout the 
course of 15 minutes, the number 
of seconds, contacts, and 
chamber entries that the rat 
allocated between the naïve and 
cage mate rat were recorded. 
Midazolam-exposed rats had 
fewer entries to both naïve and 
cagemate chamber, in 
comparison to the controls. For 
contacts, the P28 and P60 
Midazolam rats at more contacts 
for both the naïve and cage mate 
rat. However, at P45, the 
Midazolam group had less 
contacts for both naïve and cage 
mate as compared to the Saline 
group. For time spent, the 
Midazolam group only had a 
longer duration as compared to 
the Saline group in P45 for the 
naïve rat and at P60 for the cage 
mate rat. Two-Way ANOVA 
followed by a post-hoc Sidak’s
test revealed no significant 
differences (n=14-18/group). 







• From these results on the phenotypic, molecular, and behavioral level, it can be 
established that Midazolam could potentially stunt neurodevelopment during 
early stages of life/ 
• Midazolam-exposed rats display significant phenotypic alterations in their 
earlier stages of life.
• Midazolam exposure has subtle effects on expression of blood brain barrier and 
synaptic protein levels. 
• On the behavioral level, the preference of the midazolam-exposed rats to its 
cage mate (higher number of contacts) and unwillingness to explore (lower 
number of entries) can implicate a social deficit. 
• Do subtle changes in BBB and synaptic proteins impact synaptic currents (cf. 
spine density, neurotransmitter release dynamics etc.)?
• Are levels of growth factors impaired in the  midazolam exposed animals? 
• Increasing the sample size to determine potential sex-specific differences
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